Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-2,27
KB-2,12
PKN64,7664,88-5,19
Msft251,9251,93-1,12
Nokia4,83954,8431,75
IBM148,57148,62-0,40
Mercedes-Benz Group AG64,2364,240,14
PFE51,2251,230,27
02.12.2022 16:50:00
Indexy online
AD Index online
select
AD Index online
 

  • 02.12.2022 15:55:09
ReGeneRx Bio (RGRX.PK, US Other OTC (Pink Sheets))
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
0,15993 4,25 0,01 1 059
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 02.12.2022
Popis společnosti
Obecné informace
Název společnostiRegeneRx Biopharmaceuticals Inc
TickerRGRX
Kmenové akcie:Ordinary Shares
RICRGRX.PK
ISIN-
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.12.2021 3
Akcie v oběhu k 08.11.2022 143 549 735
MěnaUSD
Kontaktní informace
Ulice15245 SHADY GROVE ROAD, SUITE 470
MěstoROCKVILLE
PSČ20850
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 012 089 191
Fax13012089194

Business Summary: RegeneRx Biopharmaceuticals, Inc.(RegeneRx) is a biopharmaceutical company. The RegeneRx is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands. The Company's product candidates in clinical development includes RGN-259, RGN-352, and RGN-137. RGN -259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases. RGN-352 completed Phase I a and I b clinical trial. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, RegeneRx Biopharmaceuticals Inc revenues remained flat at $58K. Net loss increased 16% to $1.3M. Revenues reflect market conditions. Higher net loss reflects General and administrative - Balancin increase of 11% to $1.1M (expense), Gain on forgiveness of PPP loan decrease from $55K (income) to $0K, Total lease costs increase of 83% to $70K (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biopharmaceuticals
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 02.12.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Founder, Chief Scientific OfficerAllan Goldstein8401.01.1982
President, Chief Executive Officer, DirectorJ. Finkelstein7001.01.1984